Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalised COVID-19 patients

Novartis

20 April 2020 - Novartis has reached an agreement with the US FDA to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalised patients with COVID-19 disease.

Novartis has reached an agreement with the US FDA to proceed with a Phase III clinical trial with approximately 440 patients to evaluate the use of hydroxychloroquine for the treatment of hospitalised patients with COVID-19 disease. 

The clinical trial drug supply will be provided by Sandoz, the generics and biosimilars division of Novartis.

Read Novartis press release


Michael Wonder

Posted by:

Michael Wonder